Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of Kynurenic acid in Idiopathic-pulmonary-fibrosis

Next Previous
Trial Profile

A clinical trial of Kynurenic acid in Idiopathic-pulmonary-fibrosis

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 16 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Kynurenic acid (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions

Most Recent Events

  • 16 Dec 2025 New trial record
  • 02 Dec 2025 According to the BirchBioMed media release, company announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to FS2 (kynurenic acid) for the investigational treatment of idiopathic pulmonary fibrosis (IPF).
  • 02 Dec 2025 According to the BirchBioMed media release, company is seeking regulatory approval to begin clinical trials on the systemic use of FS2 for the treatment of organ fibrosis, beginning with IPF early next year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top